Arrowhead Pharmaceuticals, Inc. (ARWR)
NASDAQ: ARWR · Real-Time Price · USD
18.41
-0.30 (-1.60%)
Nov 21, 2024, 10:44 AM EST - Market open
Arrowhead Pharmaceuticals Employees
Arrowhead Pharmaceuticals had 525 employees as of September 30, 2023. The number of employees increased by 128 or 32.24% compared to the previous year.
Employees
525
Change (1Y)
128
Growth (1Y)
32.24%
Revenue / Employee
$37,425
Profits / Employee
-$1,025,973
Market Cap
2.29B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| Ardent Health Partners | 23,000 |
| UFP Technologies | 3,093 |
| iRhythm Technologies | 2,000 |
| Twist Bioscience | 919 |
| LeMaitre Vascular | 630 |
| Geron | 141 |
| IDEAYA Biosciences | 124 |
| Centessa Pharmaceuticals | 76 |
ARWR News
- 3 days ago - Arrowhead Pharmaceuticals Submits New Drug Application to U.S. FDA for Plozasiran for the Treatment of Familial Chylomicronemia Syndrome - Business Wire
- 3 days ago - Arrowhead Pharmaceuticals Presents New Data at AHA24 from PALISADE Phase 3 Study and Open-Label Extension from MUIR and SHASTA-2 Studies of Plozasiran - Business Wire
- 16 days ago - Arrowhead Pharmaceuticals to Webcast 2024 Fiscal Year End Results - Business Wire
- 17 days ago - Arrowhead Pharmaceuticals to Participate in Upcoming November 2024 Conferences - Business Wire
- 20 days ago - Arrowhead Pharmaceuticals Launches New Disease Awareness Campaign, ‘We'll Get There Soon,' to Inspire Hope for the Rare Disease Community Affected by Familial Chylomicronemia Syndrome - Business Wire
- 5 weeks ago - Arrowhead Pharmaceuticals Reports Inducement Grants under NASDAQ Listing Rule 5635(c)(4) - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals Files for Regulatory Clearance to Initiate Phase 1/2a Study of ARO-INHBE for the Treatment of Obesity - Business Wire
- 2 months ago - Arrowhead Pharmaceuticals Receives FDA Breakthrough Therapy Designation for Plozasiran - Business Wire